Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

6 results about "Tumor necrosis factor alpha" patented technology

Tumor necrosis factor (TNF, cachexin, or cachectin; once named as tumor necrosis factor alpha or TNFα) is a cell signaling protein (cytokine) involved in systemic inflammation and is one of the cytokines that make up the acute phase reaction. It is produced chiefly by activated macrophages, although it can be produced by many other cell types such as CD4+ lymphocytes, NK cells, neutrophils, mast cells, eosinophils, and neurons. TNF is a member of the TNF superfamily, consisting of various transmembrane proteins with a homologous TNF domain.

3-benzylamino coumarin compounds and uses thereof

The application belongs to the technical field of medicine, and relates to 3-benzylamino coumarin compounds and application thereof. Experimental results show that the compounds can significantly increase the survival rate of HUVEC cells in a high-sugar environment, and resist blood vessel injury caused by high sugar. The compounds can increase the release amount of NO in HUVEC cells damaged by high sugar, reduce the generation of malondialdehyde, and reduce the generation of tumor necrosis factor alpha.
Owner:JINAN SHANGCHENG MEDICAL TECH CO LTD +1

Treatment of psoriasis using small molecule inhibitors of tumor necrosis factor alpha

PendingJP2026518419AOrganic chemistryDermatological disorderTumor necrosis factor alphaPharmaceutical medicine
A treatment for psoriasis is provided herein, wherein a human subject is administered a daily dose of 400 mg of compound 1 or a pharmaceutically acceptable salt thereof.
Owner:SANOFI SA(FR)

Biomarker combination for brain function detection and application

PendingCN120870572ADisease diagnosisBiological testingGlial fibrillary acidic proteinDisease
The invention provides a biomarker combination for detecting brain functional diseases. The biomarker combination comprises four protein markers, namely a glial fibrillary acidic protein (GFAP), an interleukin-6 (IL-6), an interleukin-1beta (IL-1beta) and a tumor necrosis factor alpha (TNF-alpha). The combined detection sensitivity of GFAP, IL-6, IL-1beta and TNF-alpha in a training column set can reach 85.26%, the specificity can reach 88.04%, and the area (AUC) under an ROC curve can reach 0.866. When the blood protein marker combination is used for preparing a reagent for detecting and evaluating the brain function of a patient, the disease diagnosis sensitivity can be improved, and the blood protein marker combination has the advantages of high specificity, good stability, rapid detection and the like. The biomarker combination disclosed by the invention can be applied to products for disease risk prediction, screening, prognosis evaluation, treatment effect monitoring or relapse monitoring and the like of brain function related diseases.
Owner:SHANGHAI MENTAL HEALTH CENT (SHANGHAI PSYCHOLOGICAL COUNSELLING TRAINING CENT)

European verbena herb extract with anti-radiation effect as well as preparation method and application of European verbena herb extract

The invention discloses a verbena extract with an anti-radiation effect and a preparation method and application thereof.The preparation method comprises the specific steps that the overground part of verbena is taken, ethyl alcohol is added for heating reflux operation, and then the obtained mixed solution is filtered to obtain an extracting solution; the extraction process is repeated for 1-3 times, then extracting solutions obtained in multiple times are combined, concentration and drying treatment are carried out, and finally an extractum-like substance, namely the verbena extract, is obtained. The traditional Chinese medicine composition can effectively improve the morphology and pathological change of spleen tissues, significantly increase the counting level of peripheral blood leukocytes (WBC), neutrophils (NE) and lymphocytes (LY), and reduce the release of inflammatory factors such as tumor necrosis factor alpha (TNF-alpha), interleukin 17 (IL-17) and interleukin 6 (IL-6); in this way, the tissue damage degree caused by radiation can be practically reduced, and a potential effective intervention means is provided for treating radiation damage.
Owner:TIANJIN UNIVERSITY OF TECHNOLOGY

IFNy AND TNFa CO-STIMULATION OF MESENCHYMAL STROMAL CELLS DERIVED FROM MINOR SALIVARY (LABIAL) GLANDS FOR THERAPEUTIC USE

PendingUS20250249044A1Digestive systemSkeletal/connective tissue cellsStromal cellTumor necrosis factor alpha
Methods of preparing mesenchymal stromal cells (MSCs) through co-stimulation with interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα), and methods for using the co-stimulated MSCs to treat conditions associated with exocrine glands. Co-treatment of MSCs with IFNγ and TNFα significantly enhances their trophic secretome, preserves their immunomodulatory capacity compared to untreated MSCs, and maximizes their therapeutic efficacy. The MSCs may be allogeneic to the recipient.
Owner:WISCONSIN ALUMNI RES FOUND

IFNγ and TNFα co-stimulation of mesenchymal stromal cells derived from minor salivary (labial) glands for therapeutic use

PCT designated stageWO2025166240A1Digestive systemSkeletal/connective tissue cellsStromal cellTumor necrosis factor alpha
Methods of preparing mesenchymal stromal cells (MSCs) through co-stimulation with interferon gamma (IFNγ) and tumor necrosis factor alpha (TNFα), and methods for using the co-stimulated MSCs to treat conditions associated with exocrine glands. Co-treatment of MSCs with IFNγ and TNFα significantly enhances their trophic secretome, preserves their immunomodulatory capacity compared to untreated MSCs, and maximizes their therapeutic efficacy. The MSCs may be allogeneic to the recipient.
Owner:WISCONSIN ALUMNI RES FOUND